Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

  1. Samsung Bioepis’ biosimilar to Humira launched in the EU

    Samsung Bioepis has announced the launch of its Imraldi, an adalimumab biosimilar to Humira, in the European Union (EU); the…
    Read More…

    17 Oct
  2. Verge Genomics: employing AI to improve drug discovery

    Artificial Intelligence (AI) and machine learning has begun to dominate innovation in the medical field with the help of an…
    Read More…

    17 Oct
  3. AstraZeneca to continue UK investment freeze due to Brexit uncertainty

    Anglo-Swedish biopharma company AstraZeneca’s non-executive chairman Leif Johansson has unveiled to French newspaper La Monde that the company will continue…
    Read More…

    16 Oct
  4. AbbVie and Sandoz resolve Humira biosimilar patent dispute

    AbbVie has resolved global intellectual property litigation with Novartis subsidiary Sandoz over proposed biosimilar Hyrimoz (adalimumab) for its reference medicine…
    Read More…

    15 Oct
  5. Latin America’s medical cannabis market to reach $8.5bn by 2028

    Research consultancy Prohibition Partners has predicted that medical cannabis will account for approximately two-thirds of the total value of Latin…
    Read More…

    10 Oct
  6. World Menopause Month: moving from HRT to non-hormonal therapies

    Menopause occurs due to a change in hormone levels, mainly a reduction in oestrogen levels, causing a woman’s periods to…
    Read More…

    9 Oct
  7. Vertex’s cystic fibrosis drugs become publicly available in Denmark

    Vertex Pharmaceuticals has signed an access agreement with Denmark’s pharmaceutical procurement agency Amgros for public hospital use of all current…
    Read More…

    4 Oct
  8. NHS Genomic Medicine Service: the UK seeks to build a global genomic hub

    Hot on the heels of the success of the NHS’s 100,000 Genomes Project, which is currently 70% complete and expected…
    Read More…

    4 Oct
  9. Concerns over Brexit cause Recardio to cease clinical trials in the UK

    California-based clinical stage pharmaceutical company Recardio has halted its UK activities due to concerns over Brexit and how it will…
    Read More…

    4 Oct
  10. Masters Speciality Pharma: bringing high-quality drugs to emerging markets

    While working in the pharmaceutical industry as a regional manager for the Caribbean and Central America, Dr Zulf Masters experienced…
    Read More…

    3 Oct